Summary
Cannot verify the storage/temperature/damage/discard/room-temperature timing claims because the supplied label excerpts do not include TRULICITY storage and handling instructions. Several claims appear to be label-specific but are unsupported by the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
Trulicity (dulaglutide) pens do not require refrigeration at all times.
The provided label text contains boxed warning/contraindications/counseling and nonclinical thyroid tumor data, but does not include any storage requirements or refrigeration instructions.
Unopened Trulicity pens must be stored in the refrigerator at 36°F to 46°F (2°C to 8°C).
No storage temperature ranges for TRULICITY pens are present in the supplied label excerpts.
Unopened Trulicity pens can be kept at room temperature up to 86°F (30°C) for up to 21 days without losing potency.
No room-temperature storage duration/temperature limits are provided in the supplied label excerpts.
After first use, keep the Trulicity pen at room temperature below 86°F (30°C) for up to 21 days.
No post-first-use storage instructions are included in the supplied label excerpts.
After first use, do not return the Trulicity pen to the refrigerator.
No instruction about not returning to refrigeration after first use is included in the supplied label excerpts.
Trulicity pen should be discarded after 21 days.
No discard-after-21-days storage rule is included in the supplied label excerpts.
Trulicity pen should be discarded if expired.
No expiration-based discard guidance is included in the supplied label excerpts.
Unopened Trulicity pens can stay out for up to 21 days total.
No storage-out duration for unopened pens is included in the supplied label excerpts.
Unopened Trulicity pens are suitable for travel without cooling packs unless temperatures exceed 86°F.
No travel/cooling pack guidance or specific temperature threshold for travel is included in the supplied label excerpts.
Trulicity pens should be avoided from direct sunlight, freezing, or heat sources like cars.
No statements about avoiding sunlight/freezing/heat sources are included in the supplied label excerpts.
Trulicity prescribing information specifies to refrigerate unused pens.
The provided label excerpts do not include storage/handling instructions for unused pens.
Trulicity prescribing information specifies allowing the pen to reach room temperature before injecting (about 30 minutes).
No instruction about waiting time/bringing the pen to room temperature before injection is included in the supplied label excerpts.
Trulicity should not be used if it is frozen.
No freezing-specific use/discard instruction is included in the supplied label excerpts.
Trulicity should not be used if it is discolored.
No discolored/visual inspection instruction is included in the supplied label excerpts.
Trulicity should not be used if it is past expiration.
No expiration/use prohibition is included in the supplied label excerpts.
The storage rules for Trulicity apply to all doses (0.75 mg to 4.5 mg).
No storage rule applicability by dose strength is included in the supplied label excerpts.
If Trulicity is exposed to over 86°F for more than brief periods, the pen should be discarded and not used.
No over-temperature exposure and discard criteria are included in the supplied label excerpts.
If Trulicity is frozen, the pen should be discarded and not used.
No freezing discard/use instruction is included in the supplied label excerpts.
Heat degrades Trulicity, which is described as a protein-based drug.
The supplied label excerpts state dulaglutide is a recombinant protein (13.1), but do not provide any storage/heat degradation statements.
Freezing can cause permanent damage to Trulicity.
No freezing damage/degradation/irreversible damage statements are included in the supplied label excerpts.
Contradictions
Important Omissions
TRULICITY storage and handling instructions (refrigeration vs room temperature limits, allowable timeframes, discard criteria after first use/unopened, travel handling, and visual inspection guidance) are not present in the provided label excerpts, so label-accurate verification of the listed storage/temperature claims is not possible.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims are specific to storage conditions and discard timing, which materially affect usability/potency and are not supported by the provided label text. This creates a high risk of incorrect handling instructions being presented as label-aligned.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable with Provided Label
Primary Issue
Supplied label excerpts do not include storage/handling sections needed to verify refrigeration/temperature/time/discard claims.
Suggested Improvement
Provide the exact FDA label sections covering Storage/Handling (e.g., 'How Supplied/Storage and Handling' and any specific pen handling guidance, first-use vs unopened instructions, allowable excursions, and discard criteria). Then reassess each storage-related claim against those passages.